UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data

Nov 16 (Reuters) - Amgen Inc and Novartis said late on Wednesday that episodic migraine sufferers reported fewer debilitating headaches per month after using the companies' investigational drug erenumab, compared to trial participants who got a placebo.